Over allotment option

Hikma Pharmaceuticals Plc
30 November 2005




30 November 2005

Hikma Pharmaceuticals plc

Over Allotment Option

Not for release, publication or distribution in, or into, the United States,
directly or indirectly, Canada, Australia or Japan

Announcement of Exercise of Over-Allotment Option

Hikma Pharmaceuticals plc ('Hikma' or the 'Company') announces that, in
connection with its initial public offering of Ordinary Shares (the 'Global
Offer'), Merrill Lynch International, as stabilising manager, has given notice
to exercise the over-allotment option in respect of 260,456 Ordinary Shares in
the Company. The Company will receive gross proceeds of £755,322.40 arising from
the exercise of the over-allotment option.

Including the exercise of the over-allotment option, the gross proceeds of the
Global Offer will be £149.56 million, comprising 51.57 million Ordinary Shares.

This announcement may not be distributed, directly or indirectly, in or into the
United States, Canada, Australia or Japan. This announcement does not constitute
or form part of an offer to sell or issue, or any solicitation of an offer to
buy or subscribe for, any securities referred to herein. The Global Offer and
the distribution of this announcement and other information in connection with
the Global Offer in certain jurisdictions may be restricted by law and persons
into whose possession any document or other information referred to herein comes
should inform themselves about and observe any such restriction. Any failure to
comply with these restrictions may constitute a violation of the securities laws
of any such jurisdiction.

The securities mentioned herein have not been, and will not be, registered under
the U.S. Securities Act of 1933 (the 'Securities Act'), and may not be offered
or sold in the United States (as such term is defined in Regulation S under the
Securities Act) unless they are registered under the Securities Act or pursuant
to an exemption from registration. No public offer of the ordinary shares is
being made in the United States.

ENQUIRIES:

Hikma Pharmaceuticals PLC
Bassam Kanaan (Chief Financial Officer)                         [phone]

Brunswick
Jon Coles                                                      [phone]
Wendel Verbeek

Merrill Lynch International
Richard Girling                                                [phone]
John Plaxton
Michael Frost
Ken Lim






                      This information is provided by RNS
            The company news service from the London Stock Exchange